Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2001-12-18
pubmed:abstractText
Approximately 2/3 of patients diagnosed with superficial transitional cell carcinoma of the urinary bladder (TCC) will recur within 2 years. Loss of chromosome 9 and loss of heterozygosity (LOH) at 9q34 in index TCCs identify a subset of patients at high risk of recurrence. This study explores genetic alterations on chromosomes 4, 8, 11 and 17 as predictors of recurrence. A total of 109 carcinomas were investigated at 26 loci. DNA was extracted from microdissected archival normal/tumour tissue and was analysed for loss of heterozygosity (LOH). Fluorescent PCR was performed and genotyping carried out on a Perkin Elmer ABI377 sequencer. LOH of D11S490 or D17S928 was significantly more frequent in index carcinomas of patients who experienced recurrence compared to those with no recurrence (P = 0.004 and 0.019 respectively). These results suggest that loss of these regions is associated with recurrence of TCC. Further investigation is required to identify genes in these regions, which might be responsible for driving recurrence in TCC of the urinary bladder.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-10022124, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-10197433, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-10221333, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-10398139, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-10444335, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-10619944, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-1339926, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-2024123, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-2999610, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-7541638, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-7541642, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-7613858, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-7747807, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-7845668, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-7942844, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-8041728, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-8094291, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-8095178, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-8306342, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-8575848, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-8641139, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-8691336, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-8889509, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-8913728, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9071571, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9150366, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9160886, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9178910, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9179671, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9230190, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9256286, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9284824, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9394910, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9417908, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9649132, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9653156, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9726814, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9806178, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9812938, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9828832, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9857068, http://linkedlifedata.com/resource/pubmed/commentcorrection/11747332-9859993
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0007-0920
pubmed:author
pubmed:issnType
Print
pubmed:day
14
pubmed:volume
85
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1894-9
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:11747332-Carcinoma, Transitional Cell, pubmed-meshheading:11747332-Chromosomes, Human, Pair 11, pubmed-meshheading:11747332-Chromosomes, Human, Pair 17, pubmed-meshheading:11747332-Chromosomes, Human, Pair 4, pubmed-meshheading:11747332-Chromosomes, Human, Pair 8, pubmed-meshheading:11747332-DNA, Neoplasm, pubmed-meshheading:11747332-Disease-Free Survival, pubmed-meshheading:11747332-Female, pubmed-meshheading:11747332-Genotype, pubmed-meshheading:11747332-Humans, pubmed-meshheading:11747332-Loss of Heterozygosity, pubmed-meshheading:11747332-Male, pubmed-meshheading:11747332-Microsatellite Repeats, pubmed-meshheading:11747332-Neoplasm Recurrence, Local, pubmed-meshheading:11747332-Neoplasm Staging, pubmed-meshheading:11747332-Polymerase Chain Reaction, pubmed-meshheading:11747332-Predictive Value of Tests, pubmed-meshheading:11747332-Prognosis, pubmed-meshheading:11747332-Retrospective Studies, pubmed-meshheading:11747332-Urinary Bladder Neoplasms
pubmed:year
2001
pubmed:articleTitle
Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder.
pubmed:affiliation
University Department of Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't